Skip to main content
. 2015 Sep 18;7(20):2245–2263. doi: 10.4254/wjh.v7.i20.2245

Table 4.

Clinical side effects induced by sorafenib in patients with advanced hepatocellular carcinoma and association with outcome

Ref. Side effect Patients (n) Study design Impact on survival Impact on other parameters Predictive value
Otsuka et al[42] Skin reaction 94 Retrospective Better OS No impact on ORR, DCR, and TTP No
Vincenzi et al[45] 65 Retrospective Trend to a better OS Better DCR Early skin toxicity could predict efficacy of sorafenib
Better TTP
Di Costanzo et al[43] 65 Retrospective Better OS Not reported Skin toxicity could predict survival
Shomura et al[44] 37 Retrospective Better OS Better DCR Skin toxicity could predict efficacy
Reig et al[46] 147 Prospective Better OS Better TTP Early skin reaction could predict efficacy of sorafenib and survival
Otsuka et al[42] Arterial hypertension 94 Retrospective No impact No impact No
Estfan et al[55] 41 Retrospective Better OS Trend to better TTP

DCR: Disease control rate; OS: Overall survival; ORR: Objective response rate; TTP: Time to progression.